Development of new strategies to prevent type diabetes:: the role of animal models

被引:8
作者
Hänninen, A
Hamilton-Williams, E
Kurts, C
机构
[1] Turku Univ, Medicity Res Lab, Turku 20520, Finland
[2] Natl Publ Hlth Inst, Dept, Turku, Finland
[3] Rhein Westfal TH Aachen, Dept Nephrol & Clin Immunol, Clin, D-5100 Aachen, Germany
[4] Univ Klinikum Bonn, Inst Mol Med & Expt Immunol, Bonn, Germany
关键词
antigen-presentation; dendritic cells; disease prevention; immunological tolerance; non-obese diabetic mice; T-lymphocytes; transgenic animal models; type; 1; diabetes;
D O I
10.1080/07853890310014597
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Type 1 diabetes is an immune-mediated disease typically preceded by a long preclinical stage during which a growing number of islet-cell-specific autoantibodies appear in the serum. Although antigen-specific T lymphocytes and cytokines rather than these autoantibodies are the likely executors of beta-cell-destruction, these autoantibodies reflect the existence of autoimmunity that targets islet beta-cells. Abrogation of this autoimmunity during the preclinical stage would be the key to the prevention of type 1 diabetes. However, the quest of protecting islet-cells from the immune attack requires detailed knowledge of mechanisms that control islet-inflammation and beta-cell-destruction, and of mechanisms that control immune tolerance to peripheral self-antigens in general. This knowledge can only be obtained through further innovative research in experimental animal models. In this review, we will first examine how research in non-obese diabetic mice has already led to promising new strategies of diabetes prevention now being tested in human clinical trials. Thereafter, we will discuss how recent advances in understanding the mechanisms that control immune response to peripheral self-antigens such as beta-cell antigens may help to develop even more selective and effective strategies to prevent diabetes in the future.
引用
收藏
页码:546 / 563
页数:18
相关论文
共 187 条
[1]   Functional diversity of helper T lymphocytes [J].
Abbas, AK ;
Murphy, KM ;
Sher, A .
NATURE, 1996, 383 (6603) :787-793
[2]   Prevention of diabetes mellitus in the non-obese diabetic mouse strain with monoclonal antibodies against the CD45RB molecule [J].
Abu-Hadid, MM ;
Lazarovits, AI ;
Madrenas, J .
AUTOIMMUNITY, 2000, 32 (01) :73-76
[3]   CD4+ T cell tolerance to parenchymal self-antigens requires presentation by bone marrow-derived antigen-presenting cells [J].
Adler, AJ ;
Marsh, DW ;
Yochum, GS ;
Guzzo, JL ;
Nigam, A ;
Nelson, WG ;
Pardoll, DM .
JOURNAL OF EXPERIMENTAL MEDICINE, 1998, 187 (10) :1555-1564
[4]   Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting allograft rejection and autoimmune diseases [J].
Adorini, L ;
Penna, G ;
Giarratana, N ;
Uskokovic, M .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2003, 88 (02) :227-233
[5]   Understanding autoimmune diabetes: insights from mouse models [J].
Adorini, L ;
Gregori, S ;
Harrison, LC .
TRENDS IN MOLECULAR MEDICINE, 2002, 8 (01) :31-38
[6]  
Akerblom HK, 1998, DIABETES METAB REV, V14, P31, DOI 10.1002/(SICI)1099-0895(199803)14:1&lt
[7]  
31::AID-
[8]   Dendritic cells acquire antigen from apoptotic cells and induce class I restricted CTLs [J].
Albert, ML ;
Sauter, B ;
Bhardwaj, N .
NATURE, 1998, 392 (6671) :86-89
[9]   Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide [J].
Alleva, DG ;
Gaur, A ;
Jin, LP ;
Wegmann, D ;
Gottlieb, PA ;
Pahuja, A ;
Johnson, EB ;
Motheral, T ;
Putnam, A ;
Crowe, PD ;
Ling, N ;
Boehme, SA ;
Conlon, PJ .
DIABETES, 2002, 51 (07) :2126-2134
[10]   CD154-dependent priming of diabetogenic CD4+ T cells dissociated from activation of antigen-presenting cells [J].
Amrani, A ;
Serra, P ;
Yamanouchi, J ;
Han, BY ;
Thiessen, S ;
Verdaguer, J ;
Santamaria, P .
IMMUNITY, 2002, 16 (05) :719-732